CWP 232291

Drug Profile

CWP 232291

Alternative Names: CWP 291; CWP232291

Latest Information Update: 15 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JW Pharmaceutical
  • Developer JW Pharmaceutical; National Cancer Center (Korea)
  • Class Antineoplastics; Peptidomimetics; Small molecules
  • Mechanism of Action Beta catenin inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Multiple myeloma
  • Preclinical Gastrointestinal cancer; Solid tumours

Most Recent Events

  • 02 Jun 2017 Preclinical trials in Gastrointestinal cancer in South Korea (Intraperitoneal) before June 2017
  • 02 Jun 2017 Pharmacodynamics data from preclinical studies in Gastrointestinal cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 Mar 2017 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy) in South Korea (IV) (NCT03055286)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top